Biological mass spectrometry has evolved as a core analytical technology in the last decade mainly because of its unparalleled ability to perform qualitative as well as quantitative profiling of enormously complex biological samples with high mass accuracy, sensitivity, selectivity and specificity. 
As the target populations for the vaccines are healthy individuals, pregnant women, or infants, vaccine safety is of paramount importance. Appropriately, the vaccine landscape is changing from traditional vaccine approaches to cost-effective, highly scalable, and safe recombinant vaccines. 9, 10 Using recombinant DNA technology, antigens are expressed in yeast, Escherichia coli, baculovirus expression vector system (BEVS), or mammalian cell lines. [11] [12] [13] Recombinant antigens are engineered to mimic the first step of virus attachment to the cell surface which is mediated by specific glycoproteins. The expressed recombinant antigens undergo multiple purification cycles to produce highly purified vaccines. 14, 15 In order for recombinant vaccines to be acceptable to regulatory authorities, in-depth analytical characterization needs to be performed on the clinical trial material (CTM) to ensure the vaccine is safe and Another regulatory prerequisite is to perform extensive physiochemical characterization of these recombinant antigens. Mass spectrometry is the method of choice to perform the comprehensive physiochemical characterization of glycoproteins. Mass spectrometry-based characterization is critical not only from the standpoint of understanding the product's structure but also to help establish clinical trial material release specifications and to ensure quality ( Figure 1 ).
FIGURE 1
Analytical methods for in-process and batch release testing of the proteins based vaccines clinical trial material. A, Quality controlled analytical testing for the batch release and stability assessment of the proteins based vaccines and the list of typical parameters which should be considered during the assay validation (or qualification) of analytical method, as per ICH Q2 (R1) guidelines. B, Mass spectrometry based physiochemical characterization testing of the proteins based vaccines Thus, innovative vaccine structural design followed by comprehensive analytical characterization is required to successfully develop novel vaccines against epidemic infectious diseases impacting large segments of the global population.
In this review, we focus on the expanding role of mass spectrometry in vaccine development, irrespective of the route of production. We also highlight the regulatory challenges and limitations of mass spectrometry-based techniques which constrain its further implementation as a quality control batch release assay in cGMP manufacturing.
| ROLE OF MASS SPECTROMETRY IN THE VACCINE DEVELOPMENT
The role of mass spectrometry (MS) has been very limited in the Alternatively, an O-linked glycan can be formed by linking the oligosaccharide to a serine or threonine residue. Glycosylation play a fundamental role in antigen conformation, folding, stability, solubility, and importantly, immune response. 16, 17 Plants, yeasts, and non-human cell lines generate glycans that are not compatible and bioactive within human hosts. 18 Thus, about 70% of all recombinant glycoproteins are produced in mammalian-based expression systems such as Chinese
Hamster Ovary (CHO) cells. 19 Analytical characterization of a glycoprotein is challenging as there is inherent unpredictability associated with the glycans; they are either macroheterogeneous (potential glycan site in the protein not glycosylated) or microheterogeneous (different glycan structures found on the same site in the expressed protein). Glycosylation analysis is performed to understand the nature of structural heterogeneity of glycans, quantify them, and more importantly to determine where glycosylation occurs (site specific analysis). Mass spectrometry based techniques are valuable tool for detecting and investigating glycosylation ( Figure 2 ). Although MS-based glycosylation analysis is not without limitations, the advances in MS instrumentation and glycan analysis software have led to increased resolution, automated identification, quantitative determination, and accurate structural characterization. 16, 20, 21 Another critical quality attribute (CQA) of glycoprotein is intramolecular disulfide bonds (S-S linkages); they ensure correct folding, functional activity and stability. Incorrect formation of disulfide bonds can cause protein misfolding which tends to promote aggregation which could result in an unwarranted immune response.
Confirmation of correct disulfide bond formation in the recombinant Comprehensive mass spectrometric analysis of the site-specific glycosylation of gp120.
LC-ESI-MS was performed using an ion trap as well as a Q-TOF instrument and standard software for glycopeptide identification.
Pabst et al 112 
HIV gp120
1086.C Env expressed in CHO and HEK293 cell lines.
Evaluated and compared the host-cell specific glycosylation pattern of recombinant HIV-1 gp120 expressed in CHO and 293T cell lines.
An integrated glycopeptide-based LC-MS/MS mapping workflow that includes a partial deglycosylation step, fragmentation techniques (ETD and CID) was carried out using a hybrid LC-ESI-LTQ-FTICR MS.
Go et al 45 
Expressed in HEK293 and ACH-2 cell lines.
LC-MS/MS based site-specific glycosylation profiling of recombinant gp120 was performed using a novel spectral-aligning strategy.
MS analysis was performed using a Thermo Q Exactive mass spectrometer via higher energy collisional dissociation and spectralaligning strategy.
Yang et al 21 HIV gp120 C97ZA012 gp140 trimeric Env expressed in HEK293T cell lines (transiently & stably expressed).
Mass spectrometry based glycosylation and disulfide bond analysis of transiently and stably expressed clade C HIV-1 gp140 trimers in 293T cells.
High-and low-resolution LC-MS experiments were performed using two different platforms; LC-ESI-LTQ-FTICR MS coupled to a nanoAcquity UPLC system and the second was an LTQ Velos mass spectrometer with ETD (ThermoScientific) coupled to Acquity UPLC system (Waters). Global N-Glycan site occupancy of HIV-1 gp120 by metabolic engineering and high-resolution intact mass spectrometry was performed.
Released N-glycan analysis was carried out using Synapt G2Si ion mobility mass spectrometer. Native highresolution mass spectrometry was performed on Q Exactive hybrid Quadrupole-Orbitrap mass spectrometer. Quantification of immunoreactive viral influenza proteins using an immunocapture isotope dilution mass spectrometry (IC-IDMS) method.
The captured proteins were digested, and evolutionarily conserved tryptic peptides were quantified using IDMS-MRM approach performed using Thermo Quantum TSQ mass spectrometer with an electrospray interface.
Pierce et al LC/MS/MS method was performed for the absolute quantification of viral proteins in a complex mixture.
IDMS and MRM approach was performed using a Symmetry300 reverse phase C18 column and Thermo Quantum TSQ mass spectrometer with an electrospray interface.
Williams et al protein is ensured by mapping the scrambling of disulfide bonds using LC-MS/MS-based methods. 22 Additionally, LC-MS/MS-based methods are being increasingly used for the identification and quantification of host cell proteins (HCPs) for the antigen produced in the CHO cells. 23 As illustrated in the following section and in Table 1 
| Human immunodeficiency virus (HIV)
The quest for a safe and effective vaccine to protect against human immunodeficiency virus type 1 (HIV-1) infection is ongoing. Figure 3 ). The ability of ion mobility to separate the isomeric N-linked glycan was utilized to profile complex type, high-mannose isomers in the trimeric envelop. 
| Influenza
Influenza virus is a segmented, enveloped RNA virus and is among the strain. 73 In a separate study, the HA antigen yields of the vaccine strain [A/Puerto/Rico/8/34 (PR8)] was also determined using LC-IDMS-MRM. 74 The researchers at NCEH-CDC also demonstrated a unique quantification of immunoreactive viral influenza proteins by immunoaffinity capture followed by IDMS-MRM (IC-IDMS-MRM). The IC-IDMS-MRM method is truly an alternative to the approved SRID method as it has dual purpose "potency and content determination", was found to be equivalent to the SRID method and can also be used in response to a pandemic influenza threat. 75, 76 Additionally, a direct Ultra-Performance Liquid Chromatography (UPLC)-IDMS method was reported for the rapid and accurate quantification of influenza NA. 77 Label-free MS-based methods have also been reported for the simultaneous identification and quantification of HA and NA in influenza vaccine with samples analyzed by LC-MS E on a Waters Synapt G2 mass spectrometer. 78 Quantification of proteins by labelfree LC-MS E is a powerful tool, in this method, alternating scans of low collision energy and elevated collision energy during LC-MS analysis to obtain both protein identity and quantity in a single experiment.
Quantification based on the experimental data showed that the signal intensity was proportional to concentration which allowed for the amount of any protein in the mixture to be estimated. LC-MS E utilizes parallel, multiplex fragmentation where all peptide precursors are simultaneously fragmented throughout the chromatographic The SRID assay has been used for over 40 years as a quantitative and potency method throughout the world despite issues regarding variability and availability of standard reagents. Thus, even though new methods like HPLC and mass spectrometry are being developed, it will take some time for these methods to be adopted worldwide. As the next influenza pandemic cannot be predicted, the health authorities' pandemic preparedness efforts include efforts to ensure expedited availability of pandemic vaccines. Methods such as HPLC and MS, with their ability to quantitate antigens without standard reference reagents, can become a cornerstone of pandemic influenza preparedness.
| Dengue
The viral genus Flavivirus, includes Dengue virus, yellow fever virus, and Zika virus. Dengue represents the most common mosquito-borne disease in humans and causes ∼400 million cases of infection, ∼500 000 hospitalizations, and ∼12 500 deaths estimated to occur each year. and 153 were glycosylated and, predominately, the N-glycan at Asn67 was a high mannose-type and at Asn153 was mainly a combination of complex-and hybrid-type glycans. 87 This study provided important new insights for the role of glycans in the dengue virus-host cell interactions.
In a separate study, accurate quantitation of the expressed four viral particles in the tetravalent dengue vaccine (CYD) was performed using targeted MS in selected reaction monitoring (SRM) mode. 88 The study described an orthogonal quantitation strategy (targeted MS in SRM mode) and demonstrated that the variability of the MS method was low (between 8% and 17%) and the assay was linear between 6.25
and 200 nmol/L. Based on the reported method performance, it could be used to release future batches of the tetravalent dengue vaccine.
| Ebola
Ebola hemorrhagic fever is one of the most fatal viral diseases To improve on the conventional approaches for absolute quantitation of GP1 in Ebola virus-like particles (eVLPs), an isotope dilution full-scan liquid chromatography-high-resolution mass spectrometry method was developed using an UltiMate 3000 HPLC and an
Orbitrap Elite Hybrid Ion Trap-Orbitrap mass spectrometer. 92 The reported MS quantitation method provided not only a means to rapidly determine eVLP batch quality based upon quantitation of antigenic GP1 but also ensured adequate preclinical/clinical dosing.
| Chikungunya
Chikungunya is a mosquito-borne viral disease, endemic in Africa and Southeast Asia and has also recently emerged in the Caribbean.
Currently there are no drugs or vaccines available for treatment or prevention. The name "Chikungunya" derives from a Makonde word meaning "to become contorted," and describes the stooped appear- MS-based approaches have been used to perform the physicochemical characterization for all of these vaccines. 96 In one of the studies, researchers used LC-MS to characterize glycosylated lysine residues in Menveo®. 97 In another study a LC-MS method was used to determine the relative reactivity of lysine residues in CRM 197 to determine which of these amino acids were more susceptible to conjugation. 98 LC-MS was also used to quantify the Bexsero® vaccine which was the first vaccine developed by reverse vaccinology; a genome-based approach to vaccine development. 99 VLPs. Additionally, one post-translational modification, N-terminal acetylation, was also identified in the LI viral proteins within the VLPs.
The LC-MS peptide mapping was used to verify the batch to batch consistency and identify post-translational modifications that can occur during protein expression and purification. should be a supplemental batch release test to ensure that the product is within specifications and without any unwarranted modifications.
Using MS techniques will ensure improved quality and increased safety for clinical trial participants.
| CONCLUSION
In conclusion, the evidence suggests that the emergence of MS-based 
